stockrowValion Bio, Inc.
VBIO Healthcare Biotechnology
Valion Bio, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $780,000.00, down 33.7% from fiscal 2023.
- Revenue
- +15.9%
- EPS
- +0.91%
- Free cash flow
- −189.0%
Quarter to June 2026, against a year earlier
Follow VBIO
Alert me
Valion Bio, Inc. (VBIO) EV/Sales
As of 6 November 2026, Valion Bio, Inc. (VBIO) trades at a EV/Sales of 11.1×. Over the past ten years it has ranged from −10.0× (February 2026) to 20.2× (November 2021); the current reading is higher than 90% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | 1.2× | — |
| FY2023 | −0.4× | — |
| FY2022 | 1.3× | (59.33%) |
| FY2021 | 3.2× | (82.89%) |
| FY2020 | 18.9× | 0.00% |
| FY2019 | 18.9× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2025 | 1.3× | (78.62%) |
| Jun 2025 | 5.9× | 194.36% |
| Mar 2025 | 2.0× | 61.60% |
| Dec 2024 | 1.2× | — |
| 17 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BDRX Biodexa Pharmaceuticals PLC Unsponsored ADR compare | −2.8× |
| JAGX Jaguar Animal Health, Inc. compare | −0.1× |
| MTNB Matinas Biopharma Holdings, Inc. compare | −0.1× |
| BBLG Bone Biologics Corp. compare | n/m |
| PTIX Atrinsic Inc. compare | n/m |
| ARTL Artelo Biosciences, Inc. compare | n/m |
| LABT Lakewood-Amedex Biotherapeutics Inc. compare | n/m |
| BPTH Bio-Path Holdings, Inc. compare | n/m |
| VBIO Valion Bio, Inc. | 11.1× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)